

Haematologica
HAEMATOL/2018/203158
Version 3

Dyserythropoiesis evaluated by RED score and hepcidin/ferritin levels predicts response to erythropoietin in lower risk myelodysplastic syndromes

Sophie Park, Olivier Kosmider, Frédéric Maloisel, Bernard Drenou, Nicolas Chapuis, Thibaud Lefebvre, Zoubida Karim, Hervé Puy, Anne Sophie Alary, Sarah Ducamp, Frédérique Verdier, Cécile Bouilloux, Alice Rousseau, Marie-Christine Jacob, Agathe Debliquis, Agnes Charpentier, Emmanuel Gyan, Bruno Anglaret, Cecile Leyronnas, Selim Corm, Bohrane Slama, Stephane Cheze, Kamel Laribi, Shanti Amé, Christian Rose, Florence Lachenal, Andrea Toma, Gian Matteo Pica, Martin Carre, Frédéric Garban, Clara Mariette, Jean-Yves Cahn, Mathieu Meunier, Olivier Herault, Pierre Fenaux, Orianne Wagner-Ballon, Valerie Bardet, Francois Dreyfus, and Michaela Fontenay

Disclosures: Sophie Park has received research funding from Hospira/Pfizer. The remaining authors declare no competing financial interests.

Contributions: Sophie Park, Michaela Fontenay and Olivier Kosmider designed the study and wrote the paper. Sophie Park designed the clinical trial and performed statistical calculations. Alice Rousseau, Anne Sophie Alary and Sarah Ducamp Olivier Kosmider, Frédérique Verdier, Thibaud Lefebvre and Zoubida Karim performed experiments, analysed and interpreted data. Cécile Bouilloux recorded patients and clinical data. All the other co-authors recruited the patients in the trial and approved the paper.